Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss....
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1999
|
| _version_ | 1826288819082625024 |
|---|---|
| author | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P |
| author_facet | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P |
| author_sort | Cooper, C |
| collection | OXFORD |
| description | A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses. |
| first_indexed | 2024-03-07T02:19:28Z |
| format | Journal article |
| id | oxford-uuid:a3694a3c-e9f3-4336-a40f-ccde29c37de1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:19:28Z |
| publishDate | 1999 |
| record_format | dspace |
| spelling | oxford-uuid:a3694a3c-e9f3-4336-a40f-ccde29c37de12022-03-27T02:26:41ZMatrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a3694a3c-e9f3-4336-a40f-ccde29c37de1EnglishSymplectic Elements at Oxford1999Cooper, CStakkestad, JRadowicki, SHardy, PPilate, CDain, MDelmas, PA total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses. |
| spellingShingle | Cooper, C Stakkestad, J Radowicki, S Hardy, P Pilate, C Dain, M Delmas, P Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title | Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title_full | Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title_fullStr | Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title_full_unstemmed | Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title_short | Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. |
| title_sort | matrix delivery transdermal 17beta estradiol for the prevention of bone loss in postmenopausal women the international study group |
| work_keys_str_mv | AT cooperc matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT stakkestadj matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT radowickis matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT hardyp matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT pilatec matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT dainm matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup AT delmasp matrixdeliverytransdermal17betaestradiolforthepreventionofbonelossinpostmenopausalwomentheinternationalstudygroup |